27 completed, 8 terminated, 1 withdrawn. 24 Phase 2, 19 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 16, Terminated 7, Withdrawn 1 |
| Phase 1 | 19 | Completed 14, Terminated 5 |
| Phase 3 | 2 | Completed 2 |
Follow vatalanib: new trials by email Literature Review of vatalanib trials Research Report on vatalanib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors vatalanib, pemetrexed disodium, pharmacological study - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Mayo Clinic | 29 | 2007-01-25 | 2019-04-08 |
| PTK/ZK in Disseminated Malignant Melanoma PTK787/ZK 222584, Dacarbazine - Melanoma | Phase 1 / Phase 2 | Terminated | Michael Weichenthal | 9 | 2006-12-01 | 2021-10-06 |
| PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs PTK787/ZK 222584, Temozolomide, Radiation Therapy - Glioblastoma | Phase 1 | Completed | Massachusetts General Hospital | 19 | 2006-09-01 | 2013-10-21 |
| A Drug-drug Interaction Study of Oral 1250 mg of Vatalinib Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor in Healthy Sterile or Postmenopausal Female Volunteers Vatalinib - Healthy | Phase 1 | Completed | Novartis | 24 | 2006-07-01 | 2009-11-19 |
| Vatalanib in Treating Patients With Recurrent or Progressive Meningioma vatalanib - Brain and Central Nervous System Tumors, Sarcoma | Phase 2 | Completed | Northwestern University | 25 | 2006-05-01 | 2018-10-26 |
| Trial of PTK787/ZK 222584 Plus Paclitaxel PTK787/ZK 222584, paclitaxel - Metastatic Non-hematologic Malignancies | Phase 1 | Terminated | Dana-Farber Cancer Institute | 7 | 2006-04-26 | 2022-04-29 |
| PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer PTK787/ZK222584, Letrozole - Breast Neoplasms | Phase 2 | Terminated | Washington University School of Medicine | 4 | 2006-03-01 | 2013-05-07 |
| Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery vatalanib - Melanoma (Skin) | Phase 2 | Completed | Cambridge University Hospitals NHS Foundation Trust | 34 | 2006-02-01 | 2013-08-02 |
| Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer PTK787 and Pemetrexed with or without Cisplatin - Non-Small Cell Lung Cancer and Pleural Mesothelioma | Phase 1 / Phase 2 | Terminated | Nevada Cancer Institute | 20 | 2006-01-01 | 2012-03-19 |
| PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma PTK787/ZK222584 - Neoplasm | Phase 2 | Completed | Pancreatic Cancer Research Team | 67 | 2005-12-01 | 2012-05-09 |
| PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma PTK787 - Lymphoma, Large-Cell, Diffuse | Phase 2 | Terminated | David Rizzieri, MD | 20 | 2005-11-01 | 2014-12-09 |
| Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients Docetaxel, PTK787 - Ovarian Cancer, Endometrial Cancer | Phase 1 | Completed | Dana-Farber Cancer Institute | 24 | 2005-09-01 | 2018-07-27 |
| PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma PTK787/ZK 222584 - Multiple Myeloma | Phase 2 | Terminated | Washington University School of Medicine | 21 | 2005-09-01 | 2014-09-17 |
| Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) PTK787, Placebo - Wet Age-Related Macular Degeneration | Phase 1 / Phase 2 | Completed | Novartis | 50 | 2005-09-01 | 2008-11-14 |
| Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma hydroxyurea, imatinib mesylate, vatalanib - Brain and Central Nervous System Tumors | Phase 1 | Completed | Duke University | 37 | 2005-07-01 | 2015-10-14 |
| Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer PTK787 - Prostate Cancer | Phase 2 | Completed | University of Michigan Rogel Cancer Center | 5 | 2005-07-01 | 2015-01-19 |
| Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme temozolomide, vatalanib, adjuvant therapy - Brain and Central Nervous System Tumors | Phase 1 / Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 20 | 2005-06-01 | 2012-09-24 |
| Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors Paclitaxel plus PTK787 - Neoplasm Metastasis, Carcinoma | Phase 1 | Completed | Indiana University | 28 | 2005-05-01 | 2014-09-11 |
| Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer. SH T00268C, PTK787/ ZK 222584 - Non Small Cell Lung Cancer | Phase 2 | Completed | Bayer | 112 | 2005-03-01 | 2014-12-16 |
| Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer docetaxel, prednisone, vatalanib - Prostate Cancer | Phase 1 / Phase 2 | Terminated | University of California, San Francisco | 6 | 2005-02-01 | 2012-10-11 |
Showing 20 of 36. Sign in to see all of them.
Breast Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (3) · Central Nervous System Neoplasms (3) · Glioblastoma (3) · Melanoma (3) · Neoplasm Metastasis (3) · Neoplasms (3) · Brain Neoplasms (2) · Carcinoma, Islet Cell (2) · Carcinoma, Renal Cell (2) · Colonic Neoplasms (2) · Colorectal Neoplasms (2) · Gastrinoma (2) · Gliosarcoma (2) · Glucagonoma (2)
Novartis (4) · Dana-Farber Cancer Institute (3) · Alliance for Clinical Trials in Oncology (2) · Mayo Clinic (2) · Novartis Pharmaceuticals (2) · Washington University School of Medicine (2) · Bayer (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Daniel George, MD (1) · David Rizzieri, MD (1) · Duke University (1) · Eastern Cooperative Oncology Group (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · George Albert Fisher (1) · Hoosier Cancer Research Network (1)
United States (28) · Germany (5) · Australia (3) · Belgium (3) · France (3) · Italy (3) · Switzerland (3) · United Kingdom (3) · Brazil (2) · Canada (2) · Netherlands (2) · New Zealand (2) · Portugal (2) · Slovakia (2) · Spain (2)
Alba A. Brandes, MD (1) · Cynthia Ma, M.D., Ph.D. (1) · Daniel J. George, MD (1) · David A Rizzieri, MD (1) · David A. Reardon, MD (1) · Eric J. Small, MD (1) · Gabriela Chiorean, MD (1) · George Albert Fisher M.D. Ph.D. (1) · Heikki Joensuu, M.D. (1) · Howard A Burris, III, M.D. (1) · Jeffrey J. Raizer, MD (1) · Julian Molina (1) · Julian R. Molina, M.D., Ph.D. (1)
PMID 19248046, PMID 19945857, PMID 20800475, PMID 20821342, PMID 21464401, PMID 21464406, PMID 21617019, PMID 22197613, PMID 23700288
U10CA031946 (2), 2004 (1), P30CA015083 (1)